Current treatment options for dermatofibrosarcoma protuberans

Expert Review of Anticancer Therapy

Volumn 15, Issue 8, 2015, Pages 901-909

  Rutkowski, Piotr ^a   Debiec Rychter, Maria ^b  

^a INSTITUTE OF ONCOLOGY   (Poland)

^b UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

dermatofibrosarcoma protuberans; imatinib; molecular targeted therapy; neoadjuvant therapy; tyrosine kinase inhibitor

Indexed keywords

IMATINIB; SORAFENIB; SUNITINIB; ANTINEOPLASTIC AGENT; PLATELET DERIVED GROWTH FACTOR; PROTEIN KINASE INHIBITOR;

CANCER ADJUVANT THERAPY; CANCER REGRESSION; CANCER RESISTANCE; CARCINOGENESIS; CHEMOSURGERY; CHROMOSOME REARRANGEMENT; DERMATOFIBROSARCOMA PROTUBERANS; DRUG DOSE REDUCTION; DRUG EFFICACY; HISTOPATHOLOGY; HUMAN; MOLECULAR DIAGNOSIS; MOLECULAR PATHOLOGY; MOLECULARLY TARGETED THERAPY; NEEDLE BIOPSY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL (TOPIC); PROGRESSION FREE SURVIVAL; PROTEIN PHOSPHORYLATION; RECURRENCE RISK; REVIEW; SKIN TRANSPLANTATION; SPLIT THICKNESS SKIN GRAFT; TREATMENT DURATION; TREATMENT RESPONSE; WIDE EXCISION; ADJUVANT RADIOTHERAPY; DERMATOFIBROSARCOMA; GENETICS; METASTASIS; MULTIMODALITY CANCER THERAPY; PATHOLOGY; PROCEDURES; SKIN NEOPLASMS; UPREGULATION;

ANTINEOPLASTIC AGENTS; COMBINED MODALITY THERAPY; DERMATOFIBROSARCOMA; HUMANS; NEOPLASM METASTASIS; PLATELET-DERIVED GROWTH FACTOR; PROTEIN KINASE INHIBITORS; RADIOTHERAPY, ADJUVANT; SKIN NEOPLASMS; UP-REGULATION;

EID: 84937950895     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/14737140.2015.1052799     Document Type: Review

References (95)

1. Lemm D, Mugge LO, Mentzel T, et al. Current treatment options in dermatofibrosarcoma protuberans. J Cancer Res Clin Oncol 2009;135:653-65
2. Chang CK, Jacobs IA, Salti GI. Outcomes of surgery for dermatofibrosarcoma protuberans. Eur J Surg Oncol 2004;30: 341-5
3. Laskin WB. Dermatofibrosarcoma protuberans. CA Cancer J Clin 1992;42: 116-25
4. Bowne WB, Antonescu CR, Leung DHY, et al. Dermatofibrosarcoma protuberans. A clinicopathological analysis of patients treated and followed at a single institution. Cancer 2000 88:2711-20
5. Liang CA, Jambusaria-Pahlajani A, Karia PS, et al. A systematic review of outcome data for dermatofibrosarcoma protuberans with and without fibrosarcomatous change. J Am Acad Dermatol 2014;71:781-6
6. Mentzel T, Beham A, Katenkamp D, et al. Fibrosarcomatous 'high-grade' dermatofibrosarcoma protuberans: clinicopathological and immunohistochemical study of 41 cases with emphasis on prognostic significance. Am J Surg Pathol 1998;22:576-87
7. Lal P, Sharma R, Mohan H, Sekhon MS. Dermatofibrosarcoma protuberans metastasizing to lymph nodes: a case report and review of literature. J Surg Oncol 1999;72:178-80
8. Diaz-Cascajo C, Weyers W, Bornego L, et al. Dermatofibrosarcoma protuberans with fibrosarcomatous areas: a clinico-pathologic and immunohistochemical study four cases. Am J Dermathopathol 1997;19:562-7
9. Stacchiotti S, Pedeutour F, Negri T, et al. Dermatofibrosarcoma protuberans-derived fibrosarcoma: clinical history, biological profile and sensitivity to imatinib. Int J Cancer 2011;129(7):1761-72
10. Fiore M, Miceli R, Mussi C, et al. Dermatofibrosarcoma protuberans treated at a single institution: a surgical disease with a high cure rate. J Clin Oncol 2005;23: 7669-75
11. Weiss SW, Nickoloff BJ. CD-34 is expressed by a distinctive cell population in peripheral nerve, nerve sheath tumors, and related lesions. Am J Surg Pathol 1993; 17(10):1039-45
12. West RB, Harvell J, Linn SC, et al. Apo D in soft tissue tumors: a novel marker for dermatofibrosarcoma protuberans. Am J Surg Pathol 2004;28(8):1063-9
13. Terrier-Lacombe MJ, Guillou L, Maire G, et al. Dermatofibrosarcoma protuberans, giant cell fibroblastoma, and hybrid lesions in children: clinicopathologic comparative analysis of 28 cases with molecular data-a study from the French Federation of Cancer Centers Sarcoma Group. Am J Surg Pathol 2003;27(1):27-39
14. Valdivielso-Ramos M, Hernanz JM. Dermatofibrosarcoma protuberans in childhood. Actas Dermosifiliogr 2012; 103(10):863-73
15. Palmerini E, Gambarotti M, Staals EL, et al. Fibrosarcomatous changes and expression of CD34+ and apolipoprotein-D in dermatofibrosarcoma protuberans. Clin Sarcoma Res 2012;2(1):4
16. Bridge JA, Neff JR, Sandberg AA. Cytogenetic analysis of dermatofibrosarcoma protuberans. Cancer Genet Cytogenet 1990;49:199-202
17. Mandahl N, Heim S, Willen H, et al. Supernumerary ring chromosome as the sole cytogenetic abnormality in a dermatofibrosarcoma protuberans. Cancer Genet Cytogenet 1990;49:273-5
18. Mandahl N, Limon J, Mertens F, et al. Ring marker containing 17q and chromosome 22 in a case of dermatofibrosarcoma protuberans. Cancer Genet Cytogenet 1996;89:88-91
19. Pédeutour F, Coindre J-M, Sozzi G, et al. Supernumerary ring chromosomes containing chromosome 17 sequences: a specific feature of dermatofibrosarcoma protuberans? Cancer Genet Cytogene 1994;76:1-9
20. Pédeutour F, Simon M-P, Minoletti F, et al. Ring 22 chromosomes in dermatofibrosarcoma protuberans are low-level amplifiers of chromosome 17 and 22 sequences. Cancer Res 1995;55:2400-3
21. Pédeutour F, Lacour JP, Perrin C, et al. Another case of t(17;22)(q22;q13) in an infantile dermatofibrosarcoma protuberans. Cancer Genet Cytogenet 1996;89:175-6
22. Pédeutour F, Simon MP, Minoletti F, et al. Translocation, t(17;22)(q22;q13), in dermatofibrosarcoma protuberans: a new tumor-associated chromosome rearrangement. Cancer Genet Cytogenet 1996;72:171-4
23. Kiuru-Kuhlefelt S, El-Rifai W, Fanburg-Smith J, et al. Concomitant DNA copy number amplification at 17q and 22q in dermatofibrosarcoma protuberans. Cancer Genet Cytogenet 2001;92:192-5
24. Linn SC, West RB, Pollack JR, et al. Gene expression patterns and gene copy number changes in dermatofibrosarcoma protuberans. Am J Pathol 2003;163:2383-95
25. Sandberg AA, Bridge JA. Updates on the cytogenetics and molecular genetics of bone and soft tissue tumors: dermatofibrosarcoma protuberans and giant cell fibroblastoma. Cancer Genet Cytogenet 2003;140:1-12
26. Sirvent N, Maire G, Pedeutour F. Genetics of dermatofibrosarcoma protuberans family of tumors: from ring chromosomes to tyrosine kinase inhibitor treatment. Genes Chromosomes Cancer 2003;37(1):1-19
27. Simon MP, Pedeutour F, Sirvent N, et al. Deregulation of the platelet derived growth factor B-chain gene via fusion with collagen gene COL1A1 in dermatofibrosarcoma protuberans and giant-cell fibroblastoma. Nature Gen 1997;15:95-8
28. Shimizu A, O'Brien KP, Sjöblom T, et al. The dermatofibrosarcoma protuberans-associated collagen type I-1/ platelet-derived growth factor (PDGF) B-chain fusion gene generates a transforming protein that is processed to functional PDGFBB. Cancer Res 1999;59: 3719-23
29. Simon M-P, Navarro M, Roux D, et al. Transforming properties of chimerical protein COL1A1-PDGFB generated by dermatofibrosarcoma protuberans-associated translocation t(17;22)(q22;q13.1). Cancer Genet Cytogenet 2001;128:82
30. McArthur G. Molecularly targeted treatment for dermatofibrosarcoma protuberans. Semin Oncol 2004;31:30-6
31. Greco A, Fusetti L, Villa R, et al. Transforming activity of the chimeric sequence formed by the fusion of collagen gene COL1A1 and the platelet derived growth factor b-chain gene in dermatofibrosarcoma protuberans. Oncogene 1998;17:1313-19
32. Greco A, Roccato E, Miranda E, et al. Growth-inhibitory effect of STI571 on cells transformed by the COL1A1/PDGF-beta rearrangement. Int J Cancer 2001;92:354-60
33. O'Brien KP, Seroussi E, Dal Cin P, et al. Various regions within the alpha-helical domain of the COL1A1 gene are fused to the second exon of the PDGFB gene in dermatofibrosarcomas and giant-cell fibroblastomas. Genes Chromosomes Cancer 1998;23:187-93
34. Macarenco RS, Zamolyi R, Franco MF, et al. Genomic gains of COL1A1-PDFGB occur in the histologic evolution of giant cell fibroblastoma into dermatofibrosarcoma protuberans. Genes Chromosomes Cancer 2008;47(3):260-5
35. Abbott JJ, Erickson-Johnson M, Wang X, et al. Gains of COL1A1-PDGFB genomic copies occur in fibrosarcomatous transformation of dermatofibrosarcoma protuberans. Modern Pathol 2006;19(11): 1512-18
36. Takahira T, Oda Y, Tamiya S, et al. Microsatellite instability and p53 mutation associated with tumor progression in dermatofibrosarcoma protuberans. Hum Pathol 2004;35(2):240-5
37. Kajihara I, Jinnin M, Harada M, et al. miR-205 down-regulation promotes proliferation of dermatofibrosarcoma protuberans tumor cells by regulating LRP-1 and ERK phosphorylation. Arch Dermatol Res 2014;306(4):367-74
38. Ugurel S, Mentzel T, Utikal J, et al. Neoadjuvant imatinib in advanced primary or locally recurrent dermatofibrosarcoma protuberans: a multicenter Phase II DeCOG trial with long-term follow-up. Clin Cancer Res 2014;20(2):499-510
39. Kerob D, Pedeutour F, Leboeuf C, et al. Value of cytogenetic analysis in the treatment of dermatofibrosarcoma protuberans. J Clin Oncol 2008;26:1757-9
40. Wang J, Morimutsu Y, Okamoto S, et al. COL1A1-PDGFB fusion transcript in fibrosarcomatous areas of six dermatofibrosarcoma protuberans. J Molec Diagn 2000;2:47-52
41. Patel KU, Szabo SS, Hernandez VS, et al. Dermatofibrosarcoma protuberans COL1A1-PDGFB fusion is identified in virtually all dermatofibrosarcoma protuberans cases when investigated by newly developed multiplex reverse transcription polymerase chain reaction and fluorescence in situ hybridization assays. Hum Pathol 2008;39:184-93
42. Walluks K, Chen Y, Woelfel C, et al. Molecular and clinicopathological analysis of dermatofibrosarcoma protuberans. Pathol Res Pract 2013;209(1):30-5
43. Salgado R, Llombart B, M Pujol R, et al. Molecular diagnosis of dermatofibrosarcoma protuberans: a comparison between reverse transcriptase-polymerase chain reaction and fluorescence in situ hybridization methodologies. Genes Chromosomes Cancer 2011;50(7):510-17
44. Szollosi Z, Scholtz B, Egervari K, Nemes Z. Transformed dermatofibrosarcoma protuberans: real time polymerase chain reaction detection of COL1A1-PDGFB fusion transcripts in sarcomatous areas. J Clin Pathol 2007;60(2):190-4
45. Llombart B, Serra-Guillén C, Monteagudo C, et al. Dermatofibrosarcoma protuberans: a comprehensive review and update on diagnosis and management. Semin Diagn Pathol 2013;30(1):13-28
46. NCCN Guidelines v. 1.2015. Dermatofibrosarcoma protuberans
47. Kimmel Z, Ratner D, Kim JYS, et al. Peripheral excision margins for dermatofibrosarcoma protuberans: a meta-analysis of spatial data. Ann Surg Oncol 2007;14:2113-20
48. Gloster HM Jr, Harris KR, Roenigk RK. A comparison between Mohs micrographic surgery and a wide surgical excision for the treatment of dermatofibrosarcoma protuberans. J Am Acad Dermatol 1996;35:82-7
49. Barnes L, Coleman JA Jr, Johnson JT. Dermatofibrosarcoma protuberans of the head and neck. Arch Otolaryngol Head Neck Surg 1984;110:398-404
50. Roses DF, Valensi Q, LaTrenta G, et al. Surgical treatment of dermatofibrosarcoma protuberans. Surg Gynec Obstet 1986;162: 449-52
51. Rutgers EJ, Kroon BB, Albus-Lutter CE, et al. Dermatofibrosarcoma protuberans: treatment and prognosis. Eur J Surg Oncol 1992;18:241-8
52. Koh CK, Ho CB, Bury HPR, et al. Dermatofibrosarcoma protuberans. Int J Derm 1995;34:256-60
53. Stojadinovic A, Karpoff HM, Antonescu CR, et al. Dermatofibrosarcoma protuberans of the head and neck. Ann Surg Oncol 2000;7:696-704
54. Ten Heuvel S, Suurmeijer A, Pras E, et al. Dermatofibrosarcoma protuberans: Recurrence is related to the adequacy of surgical margins. Eur J Surg Oncol 2010;36:89-94
55. DuBay D, Cimmino V, Lowe L, et al. Low recurrence rate after surgery for dermatofibrosarcoma protuberans. A multidisciplinary approach from a single institution. Cancer 2004;100:1008-16
56. Farma JM, Ammori JB, Zager JS, et al. Dermatofibrosarcoma Protuberans: How Wide Should We Resect? Ann Surg Oncol 2010;17:2112-18
57. Wacker J, Khan-Durani B, Hartschuh W. Modified Mohs micrographic surgery in the therapy of dermatofibrosarcoma protuberans: analysis of 22 patients. Ann Surg Oncol 2004;11:438-44
58. Khatri VP, Galante JM, Bold RJ, et al. Dermatofibrosarcoma protuberans: reappraisal of wide local excision and impact of inadequate initial treatment. Ann Surg Oncol 2003;10:1118-22
59. Meguerditchian AN, Wang J, Lema B, et al. Wide excision or Mohs micrographic surgery for the treatment of primary dermatofibrosarcoma protuberans. Am J Clin Oncol 2010;33(3):300-3
60. Serra-Guillén C, Llombart B, Nagore E, et al. Mohs micrographic surgery in dermatofibrosarcoma protuberans allows tumour clearance with smaller margins and greater preservation of healthy tissue compared with conventional surgery: A study of 74 primary cases. Br J Dermatol 2014;172(5):1303-7
61. Snow SN, Gordon EM, Larson PO, et al. Dermatofibrosarcoma protuberans: a report on 29 patients treated by Mohs micrographic surgery with long term follow-up and review of the literature. Cancer 2004;101:28-38
62. Loghdey MS, Varma S, Rajpara SM, et al. Mohs micrographic surgery for dermatofibrosarcoma protuberans (DFSP): A single-centre series of 76 patients treated by frozen-section Mohs micrographic surgery with a review of the literature. J Plast Recon Aesth Surg 2014;67:1315-21
63. Foroozan M, Sei JF, Amini M, et al. Efficacy of Mohs micrographic surgery for the treatment of dermatofibrosarcoma protuberans: systematic review. Arch Dermatol 2012;148:1055-63
64. Bogucki B, Neuhaus I, Hurst EA. Dermatofibrosarcoma protuberans: a review of the literature. Dermatol Surg 2012;38:537-51
65. Ballo MT, Zagars GK, Pisters P, et al. The role of radiation therapy in the management of dermatofibrosarcoma protuberans. Int J Radiat Oncol Biol Phys 1998;40:823-7
66. Castle KO, Guadagnolo BA, Tsai CJ, et al. Dermatofibrosarcoma Protuberans: Long-term Outcomes of 53 Patients Treated With Conservative Surgery and Radiation Therapy. Int J Radiation Oncol Biol Phys 2013;86:585-90
67. Fields RC, Hameed M, Qin L-X, et al. Dermatofibrosarcoma protuberans (DFSP): Predictors of Recurrence and the Use of Systemic Therapy. Ann Surg Oncol 2011;18:328-36
68. Rutkowski P, Wozniak A, Switaj T. Advances in molecular characterization and targeted therapy in dermatofibrosarcoma protuberans. Sarcoma 2011;2011:6
69. Sjoblom T, Shimizu A, O'Brien KP, et al. Growth inhibition of dermatofibrosarcoma protuberans tumors by the platelet-derived growth factor receptor antagonist STI571 through induction of apoptosis. Cancer Res 2001;61:5778-83
70. West RB, Rubin BP, Miller MA, et al. A landscape effect in tenosynovial giant-cell tumor from activation of CSF1 expression by a translocation in a minority of tumor cells. Proc Natl Acad Sci USA 2006;103:690-5
71. Blay JY, El Sayadi H, Thiesse P, et al. Complete response to imatinib in relapsing pigmented villonodular synovitis/ tenosynovial giant cell tumor (PVNS/ TGCT). Ann Oncol 2008;19:821-2
72. Maki RG, Awan RA, Dixon RH, et al. Differential sensitivity to imatinib of 2 patients with metastatic sarcoma arising from dermatofibrosarcoma protuberans. Int J Cancer 2002;100:623-6
73. Rubin BP, Schuetze SM, Eary JF, et al. Molecular targeting of platelet-derived growth factor B by imatinib mesylate in a patient with metastatic dermatofibrosarcoma protuberans. J Clin Oncol 2002;20:3586-91
74. Pedeutour F, Coindre JM, Nicolo G, et al. Response of metastatic dermatofibrosarcoma protuberans to imatinib mesylate. Proc Am Soc Clin Oncol 2003;23:abstract 3334
75. Ruka W, Falkowski S, Wudarska J, et al. The partial response of lung metastases arising from dermatofibrosarcoma after one month of imatinib therapy-a case report. Nowotwory-Journal of Oncology 2003;53:165-8
76. Labropoulos SV, Fletcher JA, Oliveira AM, et al. Sustained complete remission of metastatic dermatofibrosarcoma protuberans with imatinib mesylate. Anticancer Drugs 2005;16:461-6
77. Mizutani K, Tamada Y, Hara K, et al. Imatinib mesylate inhibits the growth of metastatic lung lesions in a patient with dermatofibrosarcoma protuberans. Br J Dermatol 2004;151:235-7
78. Price VE, Fletcher JA, Zielenska M, et al. Imatinib mesylate: an attractive alternative in young children with large, surgically challenging dermatofibrosarcoma protuberans. Pediatr Blood Cancer 2005; 44(5):511-15
79. McArthur GA, Demetri GD, van Oosterom AT, et al. Molecular and clinical analysis of locally advanced dermatofibrosarcoma protuberans treated with imatinib: Imatinib Target Exploration Consortium Study B2225. J Clin Oncol 2005;23:866-73
80. Heinrich MC, Joensuu H, Demetri GD, et al. Phase II, open-label study evaluating the activity of imatinib in treating life-threatening malignancies known to be associated with imatinib-sensitive tyrosine kinases. Clin Cancer Res 2008;14:2717-25
81. Rutkowski P, Van Glabbeke M, Rankin CJ, et al. Imatinib mesylate in advanced dermatofibrosarcoma protuberans (DFSP): pooled analysis of two phase. II clinical trials. J Clin Oncol 2010;28:1772-9
82. Rutkowski P, Debiec-Rychter M, Nowecki ZI, et al. Treatment of advanced dermatofibrosarcoma protuberans with imatinib mesylate with or without surgical resection. J Eur Acad Dermatol Venereol 2011;25(3):264-70
83. Gronchi A, Stacchiotti S, Pedeutour F, et al. Response to imatinib mesylate (IM) in fibrosarcoma (FS) arising in dermatofibrosarcoma protuberans (DFSP). J Clin Oncol. 2008;26(Suppl):abstract 10593
84. Kérob D, Porcher R, Vérola O, et al. Imatinib mesylate as a preoperative therapy in dermatofibrosarcoma: results of a multicenter phase II study on 25 patients. Clin Cancer Res 2010;16:3288-95
85. Lemm D, Muegge LO, Hoeffken K, et al. Remission with Imatinib mesylate treatment in a patient with initially unresectable dermatofibrosarcoma protuberans-a case report. Oral Maxillofac Surg 2008;12: 209-13
86. Han A, Chen EH, Niedt G, et al. Neoadjuvant imatinib therapy for dermatofibrosarcoma protuberans. Arch Dermatol 2009;145:792-6
87. Wicherts DA, Coevorden F, Klomp HM, et al. Complete resection of recurrent and initially unresectable dermatofibrosarcoma protuberans downsized by Imatinib. World J Surg Oncol 2013;11:59
88. Johnson-Jahangir H, Sherman W, Ratner D. Using imatinib as neoadjuvant therapy in dermatofibrosarcoma protuberans: potential pluses and minuses. J Natl Compr Canc Netw 2010;8:881-5
89. Dhir M, Crocjett DG, Stevens TM, et al. Neoadjuvant treatment of Dermatofibrosarcoma Protuberans of pancreas with Imatinib: case report and systematic review of literature. Clin Sarcoma Res 2014;4:8
90. Hong JY, Liu X, Mao M, et al. Genetic aberrations in imatinib-resistant dermatofibrosarcoma protuberans revealed by whole genome sequencing. Plos One 2013;8(7):e69752
91. Miselli F, Negri T, Gronchi A, et al. Is autophagy rather than apoptosis the regression driver in imatinib-treated gastrointestinalstromal tumors? Transl Oncol 2008;1:177-86
92. Kamar FG, Kirouz VF, Sabri AN. Dermatofibrosarcoma protuberans (DFSP) successfully treated with sorafenib: case report. Clinical Sarcoma Research 2013;3:5
93. King L, López-Terrada D, Jakacky J, et al. Primary intrathoracic dermatofibrosarcoma protuberans. Am J Surg Pathol 2012;36: 1897-902
94. Dhir M, Crockett DG, Stevens TM, et al. Neoadjuvant treatment of Dermatofibrosarcoma Protuberans of pancreas with Imatinib: case report and systematic review of literature. Clin Sarcoma Res 2014;4:8
95. Karanian M, Pérot G, Coindre JM, et al. Fluorescence in situ hybridization analysis is a helpful test for the diagnosis of dermatofibrosarcoma protuberans. Mod Pathol 2015;28(2):230-7